Filing Flows › BridgeBio Pharma (BBIO) › Q2 2026
BridgeBio Pharma (BBIO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 10, 2026
BridgeBio Pharma (BBIO) reported revenue of $244M for the second quarter 2026 (Q2 2026), +120% from a year earlier and +25% from the quarter before. Operating margin was -43.9%, net loss $156M (64.0% of revenue).
BridgeBio Pharma, Q2 2026: revenue $244M (+120% year over year), operating margin -43.9%, net loss $156M, operating cash flow −$71.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $244M | +25% | +120% |
| Operating profit | −$107M | — | — |
| Net earnings | −$156M | — | — |
| Operating cash flow | −$71.1M | — | — |
What changed
Revenue was $243.7M in Q2 2026, up 120% year over year and up 25% from the previous quarter. Net product revenue was the largest line at 91% of revenue. Net product revenue added $150.9M year over year (up 211%), 113% of the total change. License and services revenue declined 84%.
Operating costs exceeded revenue by $107.1M, an operating margin of -43.9%. Total costs grew 43% against revenue growth of 120%. The fastest-growing cost line was Cost of revenue (+312%). The quarter ended with a net loss of $155.9M, narrower than the previous quarter's $166.6M loss. Minority interests bore $3.7M of it: to shareholders the quarter was a loss of $152.2M.
Operating cash flow was −$71.1M. Non-cash charges added back $1.1M of depreciation and amortization and $44.1M of share-based compensation. Working capital and other items added $39.7M. Capital expenditures of $443K exceeded it, leaving free cash flow of −$71.5M.
Questions
What was BridgeBio Pharma's revenue in the second quarter 2026?
BridgeBio Pharma (BBIO) reported revenue of $244M for the second quarter 2026 (Q2 2026), +120% from a year earlier and +25% from the quarter before.
Was BridgeBio Pharma profitable in the second quarter 2026?
Operating loss was $107M (-43.9% of revenue) and net loss $156M.
Source: BridgeBio Pharma 10-Q on SEC EDGAR.